Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT04324125
Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC
Sponsor: Hunan Province Tumor Hospital
View on ClinicalTrials.gov
Summary
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in HER 2 insertion or amplification.
Official title: Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
70
Start Date
2020-03-24
Completion Date
2025-03-24
Last Updated
2024-09-19
Healthy Volunteers
Not specified
Conditions
Locations (1)
Yongchang Zhang
Changsha, Hunan, China